Skip to main content

Fatty Liver Disease Clinical Trials: A Step Toward Hope

Exploring advanced new possibilities for those diagnosed with nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH). Join our clinical trial in New Bedford, MA to be part of research that could shape future treatments.

Advancing Liver Health Through Clinical Trials

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver condition caused by fat buildup that triggers inflammation. If left untreated, MASH can progress to severe complications such as cirrhosis or liver cancer.

Fatty liver disease clinical trials in New Bedford, MA offer an opportunity for individuals to take part in cutting-edge research. These studies explore innovative approaches to managing and potentially treating liver conditions like metabolic dysfunction-associated steatohepatitis (MASH). By participating, you can play an essential role in improving NASH/MASH care while receiving expert medical attention.


    Please provide your contact information only.

    Fatty Liver Disease Clinical Trials

    Exploring Better Outcomes for NASH/MASH-Related Cirrhosis

    This Phase 3 study is designed to evaluate the safety and effectiveness of a study drug in individuals with compensated cirrhosis due to NASH or MASH. The goal is to determine if this investigational drug can slow or reverse liver damage while improving metabolic function. As part of this study, participants will undergo thorough health evaluations and receive consistent monitoring to ensure safety and potential benefits.

    If you or someone you know has been diagnosed with Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH), this trial may offer access to potential treatment for non-alcoholic fatty liver disease and help advance liver health research.

    Participate Today

    What You Need to Know About NASH and Fatty Liver Disease

    Nonalcoholic steatohepatitis (NASH) is the more severe form of nonalcoholic fatty liver disease (NAFLD). In NAFLD, excess fat builds up in the liver—even in people who don’t drink alcohol. While NAFLD often causes no symptoms and may be mild, it can progress to NASH, where the liver becomes inflamed and damaged.

    The liver can heal small injuries, but ongoing damage can lead to scarring (fibrosis) and, eventually, cirrhosis—a serious condition that affects how the liver works. NAFLD is the most common chronic liver disease in the U.S., affecting about 1 in 4 adults. Around 20% of these people go on to develop NASH.

    Explore new possibilities in liver health by joining a NASH/MASH clinical trial. This research opportunity offers expert medical care while aiming to improve outcomes for individuals living with fatty liver disease.

    Enroll Now

    Age:
    18 years to 80 years

    Status:

    Recruiting

    Gender:

    Both

    Location:
    New Bedford, MA
    Condition:
    NASH/MASH

    Frequently Asked Questions

    Who can participate in this clinical trial?

    Eligibility depends on factors like age, medical history, and specific diagnosis. A screening process will determine if you qualify.

    What are the benefits of participating?

    Participants receive specialized medical support, regular health monitoring, and may gain access to potential new treatments at no cost.

    Will I be compensated for participating in the trial?

    Some clinical trials offer compensation for time and travel. Details will be provided during the enrollment process.

    Get Involved in Our Clinical Trials Today

    Join us in advancing medical research and discover new treatment options that could improve your health and well-being.

    Contact Us Today
    Testimonials
    And 99+ others
    Have tried Lucida Clinical Trial
    Lucida